Dilantin Side Effects

Generic Name: phenytoin

Note: This page contains information about the side effects of phenytoin. Some of the dosage forms included on this document may not apply to the brand name Dilantin.

Not all side effects for Dilantin may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to phenytoin: oral capsule, oral capsule extended release, oral suspension, oral tablet chewable

Other dosage forms:

In addition to its needed effects, some unwanted effects may be caused by phenytoin (the active ingredient contained in Dilantin). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking phenytoin:

More common
  • Decreased coordination
  • mental confusion
  • nervousness
  • slurred speech
  • trouble with breathing, speaking, or swallowing
  • unsteadiness, trembling, or other problems with muscle control or coordination
Rare
  • Inability to move the eyes
  • increased blinking or spasms of the eyelid
  • shakiness and unsteady walk shakiness in the legs, arms, hands, or feet
  • sticking out of the tongue
  • trembling or shaking of the hands or feet
  • twitching, twisting, or uncontrolled repetitive movements of the tongue, lips, face, arms, or legs
  • uncontrolled twisting movements of the neck, trunk, arms, or legs
  • unusual facial expressions
Incidence not known
  • Abdominal or stomach pain
  • bleeding gums
  • blistering, peeling, or loosening of the skin
  • blisters, hives, or itching
  • bloating of the abdomen or stomach
  • blood in the urine or stools
  • bloody, black, or tarry stools
  • chest pain
  • chills
  • cough or hoarseness
  • dark urine
  • diarrhea
  • difficulty with moving
  • fainting spells
  • fever with or without chills
  • general feeling of discomfort or illness
  • general feeling of tiredness or weakness
  • hair loss
  • headache
  • high fever
  • irregular heartbeat
  • irritation in the mouth
  • joint or muscle pain
  • light-colored stools
  • lower back or side pain
  • muscle stiffness
  • nausea or vomiting
  • numbness, tingling, or pain in the hands or feet
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • redness and swelling of the gums
  • skin blisters
  • skin rash
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen, painful, or tender lymph glands in the neck, armpit, or groin
  • unusual bleeding or bruising
  • unusual tiredness
  • upper right abdominal or stomach pain
  • weakness
  • weight loss
  • yellow eyes or skin

Some of the side effects that can occur with phenytoin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Trouble sleeping
  • uncontrolled eye movements
Incidence not known
  • Difficulty having a bowel movement (stool)
  • enlarged lips
  • feeling of constant movement of self or surroundings
  • increased hair growth on the forehead, back, arms, or legs
  • pain of the penis on erection
  • sensation of spinning

For Healthcare Professionals

Applies to phenytoin: compounding powder, injectable solution, oral capsule, oral capsule extended release, oral suspension, oral tablet chewable

Nervous system

Chronic administration may result in memory impairment, intellectual decline, and irritability. These effects are frequently subtle. Psychiatric illness (including mania and psychosis), headaches, dyskinesias (including chorea, dystonia, and tremor), benign intracranial hypertension, opsoclonus, ophthalmoplegia, sensory polyneuropathy, cerebellar degeneration, myoclonus, parkinsonism, and asterixis have also been reported less frequently.

The pathologic characteristics of phenytoin-induced neuropathy include axonal shrinkage and secondary demyelination.

At very high plasma levels, phenytoin (the active ingredient contained in Dilantin) may rarely precipitate seizures and/or status epilepticus.[Ref]

Nervous system effects are common and frequently dose-dependent. Nystagmus, ataxia, slurred speech, impaired cognition, and diplopia frequently occur. At higher plasma levels, drowsiness, lethargy, and coma may occur.
Postmarketing reports: Vertigo[Ref]

Other

Abrupt discontinuation in epileptic patients may precipitate worsening of seizures and status epilepticus. Additionally, phenytoin (the active ingredient contained in Dilantin) may exacerbate preexisting lupus.[Ref]

Other side effects have included tibial and facial edema, altered taste, coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities.[Ref]

Local

Local side effects have included edema, discoloration, and pain of the distal limb (described as "purple glove syndrome") following peripheral IV phenytoin (the active ingredient contained in Dilantin) injection. This may or may not be associated with extravasation. Although resolution of symptoms may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting and amputation.[Ref]

Cardiovascular

Cardiovascular side effects include hypotension, bradycardia, other arrhythmias and cardiac arrest rarely. These complications are most likely to occur in patients receiving parenteral phenytoin (the active ingredient contained in Dilantin) or in patients with underlying cardiovascular disease.[Ref]

Phenytoin has been implicated as a possible cause of myocarditis related to drug hypersensitivity.[Ref]

Hypersensitivity

Hypersensitivity side effects have been reported. Phenytoin is the most common cause of the anticonvulsant hypersensitivity syndrome. A variety of hypersensitivity reactions have been reported in association with phenytoin (the active ingredient contained in Dilantin) use. Reactions frequently involve generalized rashes, eosinophilia, fever, lymphadenopathy, and hepatic derangements. Myopathy, rhabdomyolysis, renal dysfunction, disseminated intravascular coagulation, and purpura fulminans have also been reported to occur as part of a phenytoin hypersensitivity reaction.[Ref]

The constellation of findings which includes lymphadenopathy, fever, exfoliative dermatitis, eosinophilia and hepatic damage is often called "pseudolymphoma" and may be fatal.

One study has suggested that hypersensitivity to phenytoin may occur in a familial pattern.[Ref]

Hepatic

The more serious hepatic effects have often been reported in association with hypersensitivity reactions.[Ref]

Hepatic side effects including elevated liver function tests, acute hepatitis, chronic persistent hepatitis, cholestasis and fulminant hepatic failure have all been reported. Mild enzyme elevation is common and often represents enzyme induction and not hepatic pathology.[Ref]

Dermatologic

Dermatologic side effects including Stevens-Johnson syndrome, toxic epidermal necrolysis, pemphigus vulgaris, erythema multiforme, a pseudonymous fungoides syndrome, erythroderma, facial pustules, hyperpigmentation, coarsening of facial features, hirsutism, hypertrichosis (which is occasionally irreversible), and lupus-like symptoms have been reported. A case of acquired acromelanosis has been reported. Another case report has suggested that phenytoin (the active ingredient contained in Dilantin) may cause an erythematous lichenified rash of the lips.[Ref]

One study of the occurrence of subacute local cutaneous reactions in patients receiving IV phenytoin reported that 29 out of 115 patients (25.2%) had such reactions. These included 22 mild reactions and 7 moderate reactions.

Erythema multiforme is more likely if the patient is receiving concomitant X-ray therapy.[Ref]

Respiratory

Respiratory side effects including life-threatening respiratory depression may occur, particularly during acute intoxication or following rapid intravenous dosing, especially with concomitant administration of benzodiazepines and barbiturates.[Ref]

Cases of an acute pulmonary disease (which may be part of a hypersensitivity angiitis) have been reported following treatment with phenytoin. Pathologically, the disease has been described both as an interstitial pneumonitis and as a lymphocytic interstitial pneumonia.[Ref]

Oncologic

Oncologic side effects have included cases of increased frequency of malignancy (particularly Hodgkin's and non-Hodgkin's lymphoma and lung cancer) in patients taking phenytoin (the active ingredient contained in Dilantin) and other antiepileptic medications. Other investigators have not found an association with malignancy.[Ref]

Hematologic

A reversible IgA deficiency has been reported. Several case reports have suggested that phenytoin (the active ingredient contained in Dilantin) may rarely induce panhypogammaglobulinemia. Another case report has suggested that phenytoin may cause a permanent deficiency in B cell immunity.

Other case reports suggest that phenytoin may cause bone marrow granulomata formation.[Ref]

Hematologic side effects including bone marrow suppression, agranulocytosis, thrombocytopenia, pure red cell aplasia, and prothrombin deficiency have been reported rarely.[Ref]

Immunologic

One report has suggested that phenytoin (the active ingredient contained in Dilantin) therapy may be associated with the development of sarcoidosis. However, a clear relationship between sarcoidosis and phenytoin therapy has not been established.

The systemic granulomatous vasculitis associated with phenytoin requires discontinuation of phenytoin and high-dose steroid therapy.[Ref]

Immunologic side effects including a lupus-like syndrome associated with the presence of lupus anticoagulant may occur. Cases of a systemic granulomatous vasculitis and necrotizing angiitis have been reported.[Ref]

Renal

Renal side effects including nephrotic syndrome and interstitial nephritis have been reported in association with phenytoin (the active ingredient contained in Dilantin) therapy.[Ref]

Endocrine

Endocrine effects include glucose intolerance and decreases in serum T4 and FT4. Favorable changes in lipid profiles have also been reported and include elevated HDL cholesterol and lower LDL cholesterol. Increases in serum estradiol levels have been reported and may contribute to the sexual dysfunction which may occur in males treated with phenytoin (the active ingredient contained in Dilantin) Gynecomastia has also been reported. Alterations in vitamin D metabolism have been reported in patients taking phenytoin and other anticonvulsants. Hypocalcemia and osteomalacia have been reported.[Ref]

Phenytoin increases the rate of T4 and T3 metabolism and may lead to hypothyroidism in patients with hypothyroidism who are being treated with T4. Phenytoin may also cause a 20% to 40% decrease in serum total and free T4 concentrations and a smaller decrease in serum total and free T3 concentrations in patients who have no thyroid disease.

Additionally, the presence of diabetes mellitus (both types I and II) has been associated with alterations in the pharmacokinetic disposition of phenytoin. Decreases in plasma protein binding, Vmax and Vmax/Km have been reported. (Km is the serum concentration at which 50% saturation occurs and Vmax is the maximum rate of metabolism.) As a result, lower steady-state concentration of phenytoin may occur in patients with diabetes mellitus.[Ref]

Gastrointestinal

Salivary gland hypertrophy has also been reported. A single case of drug-induced esophageal stricture has been reported.[Ref]

Gastrointestinal side effects including gingival hyperplasia (in as many as 50% of treated patients) have been reported. The gingival hyperplasia associated with phenytoin is occasionally severe enough to merit surgical removal. Nausea, vomiting, and constipation have been reported.[Ref]

Musculoskeletal

Musculoskeletal side effects including myopathy in association with anticonvulsant osteomalacia has been reported in patients taking phenytoin (the active ingredient contained in Dilantin) [Ref]

Genitourinary

Genitourinary side effects have included Peyronie disease, male sexual dysfunction and, more rarely, priapism has been associated with phenytoin (the active ingredient contained in Dilantin) therapy.[Ref]

Metabolic

Metabolic side effects associated with phenytoin (the active ingredient contained in Dilantin) therapy may include significantly reduced serum and red blood cell folate levels.[Ref]

Ocular

Ocular side effects including cataracts have been reported. Several human case reports and animal studies have suggested that phenytoin (the active ingredient contained in Dilantin) may predispose patients to the development of presenile cataracts. Chronic conjunctivitis has also been reported.[Ref]

References

1. Smith KR, Goulding PM, Wilderman D, Goldfader PR, Holtermanhommes P, Wei FF "Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study." Arch Neurol 51 (1994): 653-60

2. Bauer J "Seizure-inducing effects of antiepileptic drugs: a review." Acta Neurol Scand 94 (1996): 367-77

3. Kalanie H, Niakan E, Harati Y, Rolak LA "Phenytoin-induced benign intracranial hypertension." Neurology 36 (1986): 443

4. Patten SB, Klein GM, Lussier C, Sawa R "Organic mania induced by phenytoin: a case report." Can J Psychiatry 34 (1989): 827-8

5. Pulliainen V, Jokelainen M "Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients." Acta Neurol Scand 89 (1994): 81-6

6. Harrison MB, Lyons GR, Landow ER "Phenytoin and dyskinesias: a report of two cases and review of the literature." Mov Disord 8 (1993): 19-27

7. McLain LW, Martin JT, Allen JH "Cerebellar degeneration due to chronic phenytoin therapy." Ann Neurol 7 (1980): 18-23

8. Miller WI "Phenytoin chronic toxicity and associated psychosis." Drug Intell Clin Pharm 22 (1988): 1003-4

9. Lazaro RP "Involuntary movements induced by anticonvulsant drugs." Mt Sinai J Med 49 (1982): 274-81

10. Ramirez JA, Mendell JR, Warmolts JR, Griggs RC "Phenytoin neuropathy: structural changes in the sural nerve." Ann Neurol 19 (1986): 162-7

11. Osorio I, Burnstine TH, Remler B, et al "Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients." Epilepsia 30 (1989): 230-4

12. Meador KJ, Loring DW, Abney OL, Allen ME, Moore EE, Zamrini EY, King DW "Effects of carbamazepine and phenytoin on EEG and memory in healthy adults." Epilepsia 34 (1993): 153-7

13. McDanal CE, Bolman WM "Delayed idiosyncratic psychosis with diphenylhydantoin." JAMA 231 (1975): 1063

14. Shorvon SD, Reynolds EH "Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates." J Neurol Neurosurg Psychiatry 45 (1982): 620-6

15. Reynolds EH "Mental effects of antiepileptic medication: a review." Epilepsia 24 (1983): s85-95

16. Kurata K, Kido H, Kobayashi K, Yamaguchi N "Long-lasting movement disorder induced by intravenous phenytoin administration for status epilepticus." Clin Neuropharmacol 11 (1988): 467-71

17. Sandyk R "Total external opthalmoplegia induced by phenytoin." S Afr Med J 65 (1984): 141-2

18. Yoshikawa H, Abe T, Oda Y "Extremely acute phenytoin-induced peripheral neuropathy." Epilepsia 40 (1999): 528-9

19. Smith DB, Mattson RH, Cramer JA, et al "Results of a nationwide veterans administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone." Epilepsia 28 (1987): s50-8

20. Ramana R, Silverstone PH, Lishman WA "The toxic effects of anticonvulsant drugs in long-term treatment of epilepsy." J Neurol Neurosurg Psychiatry 52 (1989): 1116

21. Alhaj E, Alhaj N "Hypothermia and phenytoin toxicity: a case report." Clin Neuropharmacol 24 (2001): 239-41

22. "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.

23. Earnest MP, Marx JA, Drury LR "Complications of intravenous phenytoin for acute treatment of seizures: recommendations for usage." JAMA 249 (1983): 762-5

24. Hayes AG, Chesney TM "Necrosis of the hand after extravasation of intravenously administered phenytoin." J Am Acad Dermatol 28 (1993): 360-3

25. Rao VK, Feldman PD, Dibbell DG "Extravasation injury to the hand by intravenous phenytoin: report of three cases." J Neurosurg 68 (1988): 967-9

26. Spengler RF, Arrowsmith JB, Kilarski DJ, et al "Severe soft-tissue injury following intravenous infusion of phenytoin: patient and drug administration risk factors." Arch Intern Med 148 (1988): 1329-33

27. Taliercio CP, Olney BA, Lie JT "Myocarditis related to drug hypersensitivity." Mayo Clin Proc 60 (1985): 463-8

28. Barron SA "Cardiac arrhythmias after small intravenous dose of phenytoin." N Engl J Med 295 (1976): 678

29. Unger AH, Sklaroff HJ "Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias: report of two cases." JAMA 200 (1967): 159-60

30. Durelli L, Mutani R, Sechi GP, et al "Cardiac side effects of phenytoin and carbamazepine: a dose related phenomenon?" Arch Neurol 42 (1985): 1067-8

31. York RC, Coleridge ST "Cardiopulmonary arrest following intravenous phenytoin loading." Am J Emerg Med 6 (1988): 255-9

32. Isenstein D, Nasraway SA "Hypotension during slow phenytoin infusion in severe sepsis." Crit Care Med 18 (1990): 1036-8

33. Targan SR, Chassin MR, Guze LB "Dilantin-induced disseminated intravascular coagulation with purpura fulminans: a case report." Ann Intern Med 83 (1975): 227-30

34. Fagelman E, Fagelman A, Shabsigh R "Efficacy, safety, and use of sildenafil in urologic practice." Urology 57 (2001): 1141-4

35. Barclay CL, McLean M, Hagen N, et al "Severe phenytoin hypersensitivity with myopathy: a case report." Neurology 42 (1992): 2303

36. Engel JN, Mellul VG, Goodman DB "Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis." Am J Med 81 (1986): 928-30

37. Korman LB, Olson MJ "Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction." Clin Pharm 8 (1989): 514-5

38. Gennis MA, Vemuri R, Burns EA, et al "Familial occurrence of hypersensitivity to phenytoin." Am J Med 91 (1991): 631-4

39. Prosser TR, Lander RD "Phenytoin-induced hypersensitivity reactions." Clin Pharm 6 (1987): 728-34

40. Mahatma M, Haponik EF, Nelson S, et al "Phenytoin-induced acute respiratory failure with pulmonary eosinophilia." Am J Med 87 (1989): 93-4

41. Powers NG, Carson SH "Idiosyncratic reactions to phenytoin." Clin Pediatr (Phila) 26 (1987): 120-4

42. Black DM, Fivenson DP "Case report of antiepileptic drug hypersensitivity reaction: pseudolymphoma syndrome." Fam Pract Res J 8 (1989): 107-11

43. Cacatian AA, Rando J "Diphenylhydantoin-induced pseudolymphoma syndrome with severe thrombocytopenia." N Y State J Med June (1981): 1085-7

44. Sherertz EF, Jegasothy BV, Lazarus GS "Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis." J Am Acad Dermatol 12 (1985): 178-81

45. Kleier RS, Breneman DL, Boiko S "Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome." Arch Dermatol 127 (1991): 1361-4

46. Mullick FG, Ishak KG "Hepatic injury associated with diphenylhydantoin therapy: a clinicopathologic study of 20 cases." Am J Clin Pathol 74 (1980): 442-52

47. Aaron JS, Bank S, Ackert G "Diphenylhydantoin-induced hepatotoxicity." Am J Gastroenterol 80 (1985): 200-2

48. Roy AK, Mahoney HC, Levine RA "Phenytoin-induced chronic hepatitis." Dig Dis Sci 38 (1993): 740-3

49. Taylor JW, Stein MN, Murphy MJ, Mitros FA "Cholestatic liver dysfunction after long-term phenytoin therapy." Arch Neurol 41 (1984): 500-1

50. Egerton-Vernon JM, Fisk MJ, Snell AP "Phenytoin-induced hepatotoxicity." N Z Med J 96 (1983): 467-9

51. Kanwar AJ, Jaswal R, Thami GP, Bedi GK "Acquired acromelanosis due to phenytoin." Dermatology 194 (1997): 373-4

52. O'Brien TJ, Meara FM, Matthews H, Vajda FJ "Prospective study of local cutaneous reactions in patients receiving IV phenytoin." Neurology 57 (2001): 1508-1510

53. Tomsick RS "The phenytoin syndrome." Cutis 32 (1983): 535-41

54. MacLeod SP, Macintyre DR "Cutaneous reaction to phenytoin." Br Dent J 171 (1991): 237

55. Schmidt D, Kluge W "Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report." Epilepsia 24 (1983): 440-3

56. Creamer JD, Whittaker SJ, Kerrmuir M, Smith NP "Phenytoin-induced toxic epidermal necrolysis: a case report." Clin Exp Dermatol 21 (1996): 116-20

57. Sehgal VN, Srivastava G "Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy." Int J Dermatol 27 (1988): 258

58. Rowe JE, Pina J, Sau P, et al "Toxic epidermal necrolysis associated with diphenylhydantoin and cranial irradiation." Int J Dermatol 30 (1991): 747-9

59. Wolf R, Kahane E, Sandbank M "Mycosis fungoides-like lesions associated with phenytoin therapy." Arch Dermatol 121 (1985): 1181-2

60. Janinis J, Panagos G, Panousaki A, Skarlos D, Athanasiou E, Karpasitis N, Pirounaki M "Stevens-Johnson syndrome and epidermal necrolysis after administration of sodium phenytoin with cranial irradiation." Eur J Cancer 29A (1993): 478-9

61. Chamberlain DW, Hyland RH, Ross DJ "Diphenylhydantoin-induced lymphocytic interstitial pneumonia." Chest 90 (1986): 458-60

62. Munn NJ, Baughman RP, Ploysongsang Y, et al "Bronchoalveolar lavage in acute drug-hypersensitivity pneumonitis probably caused by phenytoin." South Med J 77 (1984): 1594-6

63. Michael JR, Rudin ML "Acute pulmonary disease caused by phenytoin." Ann Intern Med 95 (1981): 452-4

64. Rubinstein N, Weinrauch L, Matzner Y "Generalized pruritis as a presenting symptom of phenytoin-induced Hodgkin's disease." Int J Dermatol 24 (1985): 54-5

65. Olsen JH, Boice JD, Jensen JP, Fraumeni JF "Cancer among epileptic patients exposed to anticonvulsant drugs." J Natl Cancer Inst 81 (1989): 803-8

66. Schweiger FJ, Kelton JG, Messner H, et al "Anticonvulsant-induced marrow suppression and immune thrombocytopenia." Acta Haematol 80 (1988): 54-8

67. Arbiser JL, Goldstein AM, Gordon D "Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism." J Intern Med 234 (1993): 91-4

68. Rawanduzy A, Sarkis A, Rovit RL "Severe phenytoin-induced bone marrow depression and agranulocytosis treated with human recombinant granulocyte-macrophage colony- stimulating factor. Case report." J Neurosurg 79 (1993): 121-4

69. Harrison RL, Alperin JB, Kumar D "Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use." Arch Pathol Lab Med 111 (1987): 719-22

70. Holtzer CD, Reisner-Keller LA "Phenytoin-induced thrombocytopenia." Ann Pharmacother 31 (1997): 435-7

71. Eisenstein SJ, Coleman GC "Reversible bone marrow granulomata and fever induced by phenytoin administration." J Fam Pract 29 (1989): 564-5

72. Dessypris EN, Redline S, Harris JW, Krantz SB "Diphenylhydantoin-induced pure red cell aplasia." Blood 65 (1985): 789-94

73. Travin M, Macris NT, Block JM, Schwimmer D "Reversible common variable immunodeficiency syndrome induced by phenytoin." Arch Intern Med 149 (1989): 1421-2

74. Guerra IC, Fawcett WA, Redmon AH, et al "Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity." J Allergy Clin Immunol 77 (1986): 603-8

75. Rubinstein I, Baum GL, Hiss Y, Goldhammer Y "Does prolonged use of diphenylhydantoin predispose to pulmonary sarcoidosis?" Eur Neurol 25 (1986): 281-4

76. Gaffey CM, Chun B, Harvey JC, Manz HJ "Phenytoin-induced systemic granulomatous vasculitis." Arch Pathol Lab Med 110 (1986): 131-5

77. Yermakov VM, Hitti IF, Sutton AL "Necrotizing vasculitis associated with diphenylhydantoin: two fatal cases." Hum Pathol 13 (1983): 182-4

78. Hoffman EW "Phenytoin-induced interstitial nephritis." South Med J 74 (1981): 1160-1

79. Orlandini G, Garini G "Phenytoin-induced nephrotic syndrome." Nephron 52 (1989): 109

80. Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12

81. Alderman CP, Hill CL "Abnormal bone mineral metabolism after long-term anticonvulsant treatment." Ann Pharmacother 28 (1994): 47-8

82. Bell RD, Pak CY, Zerwekh J, et al "Effect of phenytoin on bone and vitamin d metabolism." Ann Neurol 5 (1979): 374-8

83. Isojarvi JI, Pakarinen AJ, Myllyla VV "Thyroid function with antiepileptic drugs." Epilepsia 33 (1992): 142-8

84. Blackshear JL, Schultz AL, Napier JS, Stuart DD "Thyroxine replacement requirements in hypothyroid patients receiving phenytoin." Ann Intern Med 99 (1983): 341-2

85. Monson JP, Scott DF "Gynaecomastia induced by phenytoin in men with epilepsy." Br Med J 294 (1987): 612

86. Siddiqui MA "Osteomalacia and phenytoin therapy." Ann Intern Med 121 (1994): 550

87. Ronin DI, Wu Y, Sahgal V, MacLean IC "Intractable muscle pain syndrome, osteomalacia, and axonopathy in long-term use of phenytoin." Arch Phys Med Rehabil 72 (1991): 755-8

88. Schmitt BP, Nordlund DJ, Rodgers LA "Prevalence of hypocalcemia and elevated serum alkaline phosphatase in patients receiving chronic anticonvulsant therapy." J Fam Pract 18 (1984): 873-7

89. Anast CS "Anticonvulsant drugs and calcium metabolism." N Engl J Med 292 (1975): 587-8

90. Adithan C, Srinivas B, Indhiresan J, et al "Influence of type I and type II diabetes mellitus on phenytoin steady-state levels." Int J Clin Pharmacol Ther Toxicol 29 (1991): 310-3

91. Hahn TJ, Hendin BA, Scharp CR, Haddad JG "Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults." N Engl J Med 287 (1972): 900-4

92. Surks MI, Sievert R "Drugs and thyroid function." N Engl J Med 333 (1995): 1688-94

93. Calandre EP, Porta BS, de la Calzada DG "The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients." Epilepsia 33 (1992): 154-7

94. Herzog AG, Levesque LA, Drislane FW, et al "Phenytoin-induced elevation of serum estradiol and reproductive dysfunction in men with epilepsy." Epilepsia 32 (1991): 550-3

95. Brandenburg AH, Smits MG, Voorbrood BS, Hemmes AM, Ros JJ "Submandibular salivary gland hypertrophy induced by phenytoin." Epilepsia 34 (1993): 151-2

96. Bonavina L, DeMeester TR, McChesney L, et al "Drug-induced esophageal strictures." Ann Surg 206 (1987): 173-83

97. Simsek O, Ozyurt M "Phenytoin toxicity causing priapism." Br J Urol 61 (1988): 261-8

98. Goggin T, Gough H, Bissessar A, et al "A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy." Q J Med 65 (1987): 911-9

99. Bar S, Feller N, Savir H "Presenile cataracts in phenytoin-treated epileptic patients." Arch Ophthalmol 101 (1983): 422-5

100. Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971): 13-34

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)